Cardiac Science buys defibrillator company:
This article was originally published in Clinica
Cardiac Science, of Irvine, California, is to buy private R&D company HeartSine Technologies, which is developing defibrillator systems. Cardiac will issue one million shares. HeartSine, which has operations in Northern Ireland and Orange Country, California, is focused on defibrillation waveforms, cardiac arrhythmia detection algorithms and cardiac pacing. Cardiac Science says HeartSine's technologies will accelerate the integration of Cardiac's RHYTHMx ECD automatic cardiac arrest detection and treatment module into standard bedside monitoring systems.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.